Skip to content
MarketScale
‹ Back to Industries

Sciences

Terminator-Inspired Shape-Shifting Robot Becomes Reality. What Use Cases Does It Have in Manufacturing?

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist. This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers. However, that’s where the similarities end. The new robot was…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · Liquid Metal RobotMagnetoactive Phase Transitional MatterManufacturingMptm
Share

Key takeaways

01

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist.

02

This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers.

03

However, that’s where the similarities end.

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist. This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers. However, that’s where the similarities end.

The new robot was developed by a team from The Chinese University of Hong Kong under the direction of Dr. Chengfeng Pan. It is made up of a newly developed phase-shifting material researchers call “magnetoactive liquid-solid phase transitional matter,” or MPTM. Magnetic particles embedded in the material of the robot allow users to control it. This means it can be heated and cooled on demand using an alternating magnetic field to melt it into a liquid and then solidify it again.

This research is just one of the many advancements shaping the future of robotics and its use cases. Scientists are hoping that this discovery will one day be of use in a variety of fields, including medicine and assembly lines. MPTM could make it easier to solder and screw parts in hard-to-reach places, for example, but that’s hopefully just scratching the surface of its utility.

How can the manufacturing industry benefit from a shape-shifting robot? And are there any manufacturing applications where a flexible structure can make a huge difference? We reached out to Rhonda DiBachi, CEO of HeyScottie, for her expert opinion and analysis on this T-1000 tech. Rhonda has been implementing manufacturing techniques for companies since the 1980s and founded numerous startups for tech and manufacturing. 

Rhonda’s Thoughts:

“I don’t know of any manufacturing applications for this new material called MPTM or Magnetoactive Phase Transitional Matter. It’s early days. I do know of some applications of a similar kind of material called a shape memory alloy. That’s metals that change their shape depending upon changes in temperature and pressure.

I know that those are used in pneumatic and flow control systems to change valves. That’s interesting. An interesting application for this new kind of material, MPTM, I would think would be 3D printing, metal 3D printing. You could create struts using this material and when you’re building up the part you could use the struts, they would be structural.

But then when you’re done building up the part, you don’t need the struts anymore. And, if you could flip a switch and make them change their shape, they might be able to just slither out, making removal quite a bit easier than it is right now. Could be interesting.”

Article written by Sonia Gossai.

About the author

C
carey.scott

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott